Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) insider Andrew Hollman Meyer sold 3,334 shares of the company's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $30.00, for a total transaction of $100,020.00. Following the transaction, the insider now owns 82,139 shares in the company, valued at $2,464,170. The trade was a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Andrew Hollman Meyer also recently made the following trade(s):
- On Monday, March 3rd, Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock. The shares were sold at an average price of $32.15, for a total transaction of $107,188.10.
- On Monday, February 3rd, Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.29, for a total value of $140,994.86.
Janux Therapeutics Stock Performance
JANX stock opened at $31.62 on Thursday. Janux Therapeutics, Inc. has a one year low of $22.52 and a one year high of $71.71. The stock has a market capitalization of $1.87 billion, a P/E ratio of -27.03 and a beta of 3.27. The company has a 50 day moving average price of $30.29 and a two-hundred day moving average price of $43.31.
Janux Therapeutics (NASDAQ:JANX - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Research analysts forecast that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts have commented on JANX shares. Wedbush reiterated an "outperform" rating and set a $76.00 target price (up from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. Lifesci Capital raised shares of Janux Therapeutics to a "strong-buy" rating in a research note on Friday, December 27th. HC Wainwright restated a "buy" rating and set a $70.00 target price on shares of Janux Therapeutics in a research report on Monday, March 3rd. Scotiabank lowered their price target on shares of Janux Therapeutics from $62.00 to $41.00 and set a "sector perform" rating on the stock in a research report on Friday, February 28th. Finally, William Blair restated an "outperform" rating on shares of Janux Therapeutics in a research report on Friday, January 10th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $95.25.
Read Our Latest Research Report on Janux Therapeutics
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of JANX. FNY Investment Advisers LLC increased its position in Janux Therapeutics by 6,928.6% during the first quarter. FNY Investment Advisers LLC now owns 2,460 shares of the company's stock worth $66,000 after purchasing an additional 2,425 shares during the last quarter. Exchange Traded Concepts LLC increased its holdings in shares of Janux Therapeutics by 20.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 4,043 shares of the company's stock worth $109,000 after buying an additional 686 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Janux Therapeutics in the 1st quarter worth $773,000. Avanza Fonder AB boosted its holdings in Janux Therapeutics by 17.0% in the first quarter. Avanza Fonder AB now owns 3,049 shares of the company's stock valued at $86,000 after acquiring an additional 444 shares during the last quarter. Finally, Rhumbline Advisers grew its position in Janux Therapeutics by 11.8% during the first quarter. Rhumbline Advisers now owns 42,650 shares of the company's stock valued at $1,152,000 after acquiring an additional 4,497 shares during the period. 75.39% of the stock is currently owned by hedge funds and other institutional investors.
Janux Therapeutics Company Profile
(
Get Free Report)
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
